Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India-Reference-Cited by-同舟云学术

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Published:2022-04 Issue:10332 Volume:399 Page:1313-1321
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Khobragade Akash,Bhate Suresh,Ramaiah Vijendra,Deshpande Shrikant,Giri Krishna,Phophle Himanshu,Supe Pravin,Godara Inderjeet,Revanna Ramesh,Nagarkar Rajnish,Sanmukhani Jayesh,Dey Ayan,Rajanathan T M Chozhavel,Kansagra Kevinkumar,Koradia Parshottam

Publisher

Elsevier BV

Subject

General Medicine

Reference7 articles.

1. Compassionate use of remdesivir for patients with severe COVID-19;Grein;N Engl J Med,2020

2. Clinical course and mortality risk of severe COVID-19;Weiss;Lancet,2020

3. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment;Wouters;Lancet,2021

4. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, phase 2 clinical trial in adults at high risk of viral exposure;Mammen;medRxiv,2021

5. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models;Dey;Vaccine,2021

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined biolistic and cell penetrating peptide delivery for the development of scalable intradermal DNA vaccines;Journal of Controlled Release;2024-03

2. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines;Autoimmunity Reviews;2024-03

3. A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses;Frontiers in Immunology;2024-02-02

4. COVID-19 Vaccines: Where Did We Stand at the End of 2023?;Viruses;2024-01-29

5. Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials;Vaccines;2024-01-26